A Randomized, Open-label, Multiple-dose, 6-sequence, 3-treatment, 3-period, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects
Latest Information Update: 26 May 2023
At a glance
- Drugs BR 1018 (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
Most Recent Events
- 22 May 2023 Status changed from recruiting to completed.
- 23 Jul 2022 New trial record